NCT06325826View on ClinicalTrials.gov

The Study of the Validation of General Evaluation Score (GES) in the Prediction of Hepatocellular Carcinoma Risk Among Patients With Advanced Fibrosis and Cirrhosis Who Achieved Sustained Virological Response for Hepatitis C Virus After Direct Acting Antiviral Drugs

Active, not recruitingOBSERVATIONAL
Enrollment

500

Participants

Timeline

Start Date

February 1, 2022

Primary Completion Date

June 30, 2023

Study Completion Date

June 30, 2025

Conditions
Hepatocellular Carcinoma
Interventions
DIAGNOSTIC_TEST

General Evaluation Score (GES)

According to Evaluation of GES scores Patient will be classified into three groups based on GES score low risk group (score ≤6 points), intermediate risk group (score 6-7.5 points), and high-risk group (score \>7.5 points)

Trial Locations (1)

36681

Egyptian Liver Hospital, Ţalkhā

All Listed Sponsors
lead

Egyptian Liver Hospital

OTHER